BRAF and metastatic melanoma: The first two mutant-selective BRAF inhibitors to be approved in patients with metastatic melanoma were vemurafenib (FDA approval in 2011) and dabrafenib (FDA approval in 2013).20 Both of these agents achieved rapid clinical responses and symptomatic improvement in patients with a BRAFV600 mutation in early-phase clinical trials.